Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 34 entries
Sorted by: Best Match Show Resources per page
A Combination Therapy with Mitomycin C, Etoposide, Doxifluridine and Medroxyprogesterone Acetate as Second Line Therapy for Advanced Breast Cancer Refractory to Combination Chemotherapy of Cyclo-phoshamide, Doxorubicin and 5-Fluorouracil.

Breast cancer (Tokyo, Japan)

Kuroi K, Osaki A, Kawami H, Murakami S, Toge T.
PMID: 11091585
Breast Cancer. 1997 Jul 31;4(2):115-119. doi: 10.1007/BF02967064.

Thirty-two patients with advanced breast cancer refractory to combination chemotherapy with cyclophosphamide (CPA), doxorubicin (ADR) and 5-fluorouracil (5-EU) (CAF) were treated with the combination of mitomycin C, etoposide, doxifluridine and medroxyprogesterone acetate as second line therapy. Observed responses included...

Cite
Kuroi K, Osaki A, Kawami H, et al. A Combination Therapy with Mitomycin C, Etoposide, Doxifluridine and Medroxyprogesterone Acetate as Second Line Therapy for Advanced Breast Cancer Refractory to Combination Chemotherapy of Cyclo-phoshamide, Doxorubicin and 5-Fluorouracil. Breast Cancer. 1997;4(2):115-119doi: 10.1007/BF02967064.
Kuroi, K., Osaki, A., Kawami, H., Murakami, S., & Toge, T. (1997). A Combination Therapy with Mitomycin C, Etoposide, Doxifluridine and Medroxyprogesterone Acetate as Second Line Therapy for Advanced Breast Cancer Refractory to Combination Chemotherapy of Cyclo-phoshamide, Doxorubicin and 5-Fluorouracil. Breast cancer (Tokyo, Japan), 4(2), 115-119. https://doi.org/10.1007/BF02967064
Kuroi, et al. "A Combination Therapy with Mitomycin C, Etoposide, Doxifluridine and Medroxyprogesterone Acetate as Second Line Therapy for Advanced Breast Cancer Refractory to Combination Chemotherapy of Cyclo-phoshamide, Doxorubicin and 5-Fluorouracil." Breast cancer (Tokyo, Japan) vol. 4,2 (1997): 115-119. doi: https://doi.org/10.1007/BF02967064
Kuroi K, Osaki A, Kawami H, Murakami S, Toge T. A Combination Therapy with Mitomycin C, Etoposide, Doxifluridine and Medroxyprogesterone Acetate as Second Line Therapy for Advanced Breast Cancer Refractory to Combination Chemotherapy of Cyclo-phoshamide, Doxorubicin and 5-Fluorouracil. Breast Cancer. 1997 Jul 31;4(2):115-119. doi: 10.1007/BF02967064. PMID: 11091585.
Copy Download .nbib Format: NLM
Construction of synergistic pH/H.

Bioorganic chemistry

Liu J, Si S, Xu J, Xue P, Li K.
PMID: 34847429
Bioorg Chem. 2021 Nov 23;119:105510. doi: 10.1016/j.bioorg.2021.105510. Epub 2021 Nov 23.

We have developed a real-time and multifunctional doxifluridine-conjugate prodrug (LYX), which involved the preliminary methylfluorescein with 5-fluorouracil linker as protecting group, the targeting biotin unit, and a model therapeutic drug (doxifluridine). The shielding group (5'-DFUR) was found to be...

Cite
Liu J, Si S, Xu J, et al. Construction of synergistic pH/H. Bioorg Chem. 2021;119:105510doi: 10.1016/j.bioorg.2021.105510.
Liu, J., Si, S., Xu, J., Xue, P., & Li, K. (2021). Construction of synergistic pH/H. Bioorganic chemistry, 119105510. https://doi.org/10.1016/j.bioorg.2021.105510
Liu, Jun, et al. "Construction of synergistic pH/H." Bioorganic chemistry vol. 119 (2021): 105510. doi: https://doi.org/10.1016/j.bioorg.2021.105510
Liu J, Si S, Xu J, Xue P, Li K. Construction of synergistic pH/H. Bioorg Chem. 2021 Nov 23;119:105510. doi: 10.1016/j.bioorg.2021.105510. Epub 2021 Nov 23. PMID: 34847429.
Copy Download .nbib Format: NLM
Construction of synergistic pH/H.

Bioorganic chemistry

Liu J, Si S, Xu J, Xue P, Li K.
PMID: 34847429
Bioorg Chem. 2021 Nov 23;119:105510. doi: 10.1016/j.bioorg.2021.105510. Epub 2021 Nov 23.

We have developed a real-time and multifunctional doxifluridine-conjugate prodrug (LYX), which involved the preliminary methylfluorescein with 5-fluorouracil linker as protecting group, the targeting biotin unit, and a model therapeutic drug (doxifluridine). The shielding group (5'-DFUR) was found to be...

Cite
Liu J, Si S, Xu J, et al. Construction of synergistic pH/H. Bioorg Chem. 2021;119:105510doi: 10.1016/j.bioorg.2021.105510.
Liu, J., Si, S., Xu, J., Xue, P., & Li, K. (2021). Construction of synergistic pH/H. Bioorganic chemistry, 119105510. https://doi.org/10.1016/j.bioorg.2021.105510
Liu, Jun, et al. "Construction of synergistic pH/H." Bioorganic chemistry vol. 119 (2021): 105510. doi: https://doi.org/10.1016/j.bioorg.2021.105510
Liu J, Si S, Xu J, Xue P, Li K. Construction of synergistic pH/H. Bioorg Chem. 2021 Nov 23;119:105510. doi: 10.1016/j.bioorg.2021.105510. Epub 2021 Nov 23. PMID: 34847429.
Copy Download .nbib Format: NLM
Construction of synergistic pH/H.

Bioorganic chemistry

Liu J, Si S, Xu J, Xue P, Li K.
PMID: 34847429
Bioorg Chem. 2021 Nov 23;119:105510. doi: 10.1016/j.bioorg.2021.105510. Epub 2021 Nov 23.

We have developed a real-time and multifunctional doxifluridine-conjugate prodrug (LYX), which involved the preliminary methylfluorescein with 5-fluorouracil linker as protecting group, the targeting biotin unit, and a model therapeutic drug (doxifluridine). The shielding group (5'-DFUR) was found to be...

Cite
Liu J, Si S, Xu J, et al. Construction of synergistic pH/H. Bioorg Chem. 2021;119:105510doi: 10.1016/j.bioorg.2021.105510.
Liu, J., Si, S., Xu, J., Xue, P., & Li, K. (2021). Construction of synergistic pH/H. Bioorganic chemistry, 119105510. https://doi.org/10.1016/j.bioorg.2021.105510
Liu, Jun, et al. "Construction of synergistic pH/H." Bioorganic chemistry vol. 119 (2021): 105510. doi: https://doi.org/10.1016/j.bioorg.2021.105510
Liu J, Si S, Xu J, Xue P, Li K. Construction of synergistic pH/H. Bioorg Chem. 2021 Nov 23;119:105510. doi: 10.1016/j.bioorg.2021.105510. Epub 2021 Nov 23. PMID: 34847429.
Copy Download .nbib Format: NLM
Construction of synergistic pH/H.

Bioorganic chemistry

Liu J, Si S, Xu J, Xue P, Li K.
PMID: 34847429
Bioorg Chem. 2021 Nov 23;119:105510. doi: 10.1016/j.bioorg.2021.105510. Epub 2021 Nov 23.

We have developed a real-time and multifunctional doxifluridine-conjugate prodrug (LYX), which involved the preliminary methylfluorescein with 5-fluorouracil linker as protecting group, the targeting biotin unit, and a model therapeutic drug (doxifluridine). The shielding group (5'-DFUR) was found to be...

Cite
Liu J, Si S, Xu J, et al. Construction of synergistic pH/H. Bioorg Chem. 2021;119:105510doi: 10.1016/j.bioorg.2021.105510.
Liu, J., Si, S., Xu, J., Xue, P., & Li, K. (2021). Construction of synergistic pH/H. Bioorganic chemistry, 119105510. https://doi.org/10.1016/j.bioorg.2021.105510
Liu, Jun, et al. "Construction of synergistic pH/H." Bioorganic chemistry vol. 119 (2021): 105510. doi: https://doi.org/10.1016/j.bioorg.2021.105510
Liu J, Si S, Xu J, Xue P, Li K. Construction of synergistic pH/H. Bioorg Chem. 2021 Nov 23;119:105510. doi: 10.1016/j.bioorg.2021.105510. Epub 2021 Nov 23. PMID: 34847429.
Copy Download .nbib Format: NLM
In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase.

Journal of clinical medicine

Hishinuma E, Gutiérrez Rico E, Hiratsuka M, Al-Turjman F, Abujubbeh M, Malekloo A.
PMID: 32707991
J Clin Med. 2020 Jul 22;9(8). doi: 10.3390/jcm9082342.

Fluoropyrimidine drugs (FPs), including 5-fluorouracil, tegafur, capecitabine, and doxifluridine, are among the most widely used anticancer agents in the treatment of solid tumors. However, severe toxicity occurs in approximately 30% of patients following FP administration, emphasizing the importance of...

Cite
Hishinuma E, Gutiérrez Rico E, Hiratsuka M, et al. In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase. J Clin Med. 2020;9(8)doi: 10.3390/jcm9082342.
Hishinuma, E., Gutiérrez Rico, E., Hiratsuka, M., Al-Turjman, F., Abujubbeh, M., & Malekloo, A. (2020). In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase. Journal of clinical medicine, 9(8), . https://doi.org/10.3390/jcm9082342
Hishinuma, Eiji, et al. "In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase." Journal of clinical medicine vol. 9,8 (2020). doi: https://doi.org/10.3390/jcm9082342
Hishinuma E, Gutiérrez Rico E, Hiratsuka M, Al-Turjman F, Abujubbeh M, Malekloo A. In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase. J Clin Med. 2020 Jul 22;9(8). doi: 10.3390/jcm9082342. PMID: 32707991; PMCID: PMC7464968.
Copy Download .nbib Format: NLM
Long-Term Survival of a Patient with Adenocarcinoma of the Esophagogastric Junction with a Portal Vein Tumor Thrombosis Who Underwent Palliative Total Gastrectomy: A Case Report.

Case reports in oncology

Oh SD, Oh SJ, Suh BJ, Shin JY, Park JK.
PMID: 29279692
Case Rep Oncol. 2017 Oct 17;10(3):916-922. doi: 10.1159/000481430. eCollection 2017.

Portal vein tumor thrombosis (PVTT) with advanced gastric cancer is very rare; when it occurs, it exhibits aggressive growth and carries a poor prognosis. In addition, definitive treatment has not been established due to insufficient data. Herein, we report...

Cite
Oh SD, Oh SJ, Suh BJ, et al. Long-Term Survival of a Patient with Adenocarcinoma of the Esophagogastric Junction with a Portal Vein Tumor Thrombosis Who Underwent Palliative Total Gastrectomy: A Case Report. Case Rep Oncol. 2017;10(3):916-922doi: 10.1159/000481430.
Oh, S. D., Oh, S. J., Suh, B. J., Shin, J. Y., & Park, J. K. (2017). Long-Term Survival of a Patient with Adenocarcinoma of the Esophagogastric Junction with a Portal Vein Tumor Thrombosis Who Underwent Palliative Total Gastrectomy: A Case Report. Case reports in oncology, 10(3), 916-922. https://doi.org/10.1159/000481430
Oh, Sung Don, et al. "Long-Term Survival of a Patient with Adenocarcinoma of the Esophagogastric Junction with a Portal Vein Tumor Thrombosis Who Underwent Palliative Total Gastrectomy: A Case Report." Case reports in oncology vol. 10,3 (2017): 916-922. doi: https://doi.org/10.1159/000481430
Oh SD, Oh SJ, Suh BJ, Shin JY, Park JK. Long-Term Survival of a Patient with Adenocarcinoma of the Esophagogastric Junction with a Portal Vein Tumor Thrombosis Who Underwent Palliative Total Gastrectomy: A Case Report. Case Rep Oncol. 2017 Oct 17;10(3):916-922. doi: 10.1159/000481430. eCollection 2017. PMID: 29279692; PMCID: PMC5731138.
Copy Download .nbib Format: NLM
Impact of the new AJCC staging system and adjuvant treatment in rectal cancer.

Cancer research and treatment

Lee SA, Kwon HC, Park MA, Jung CK, Kim SH, Park KJ, Choi HJ, Lee HS, Roh MS, Kim JS, Kim HJ.
PMID: 20396551
Cancer Res Treat. 2004 Apr;36(2):121-7. doi: 10.4143/crt.2004.36.2.121. Epub 2004 Apr 30.

PURPOSE: The combination of chemoradiation and fluorouracil based chemotherapy has been the standard adjuvant treatment for colorectal cancer patients. The aim of this study was to evaluate treatment outcome of patients classified by the new AJCC staging system and...

Cite
Lee SA, Kwon HC, Park MA, et al. Impact of the new AJCC staging system and adjuvant treatment in rectal cancer. Cancer Res Treat. 2004;36(2):121-7doi: 10.4143/crt.2004.36.2.121.
Lee, S. A., Kwon, H. C., Park, M. A., Jung, C. K., Kim, S. H., Park, K. J., Choi, H. J., Lee, H. S., Roh, M. S., Kim, J. S., & Kim, H. J. (2004). Impact of the new AJCC staging system and adjuvant treatment in rectal cancer. Cancer research and treatment, 36(2), 121-7. https://doi.org/10.4143/crt.2004.36.2.121
Lee, Shin Ae, et al. "Impact of the new AJCC staging system and adjuvant treatment in rectal cancer." Cancer research and treatment vol. 36,2 (2004): 121-7. doi: https://doi.org/10.4143/crt.2004.36.2.121
Lee SA, Kwon HC, Park MA, Jung CK, Kim SH, Park KJ, Choi HJ, Lee HS, Roh MS, Kim JS, Kim HJ. Impact of the new AJCC staging system and adjuvant treatment in rectal cancer. Cancer Res Treat. 2004 Apr;36(2):121-7. doi: 10.4143/crt.2004.36.2.121. Epub 2004 Apr 30. PMID: 20396551; PMCID: PMC2855093.
Copy Download .nbib Format: NLM
Construction of synergistic pH/H.

Bioorganic chemistry

Liu J, Si S, Xu J, Xue P, Li K.
PMID: 34847429
Bioorg Chem. 2021 Nov 23;119:105510. doi: 10.1016/j.bioorg.2021.105510. Epub 2021 Nov 23.

We have developed a real-time and multifunctional doxifluridine-conjugate prodrug (LYX), which involved the preliminary methylfluorescein with 5-fluorouracil linker as protecting group, the targeting biotin unit, and a model therapeutic drug (doxifluridine). The shielding group (5'-DFUR) was found to be...

Cite
Liu J, Si S, Xu J, et al. Construction of synergistic pH/H. Bioorg Chem. 2021;119:105510doi: 10.1016/j.bioorg.2021.105510.
Liu, J., Si, S., Xu, J., Xue, P., & Li, K. (2021). Construction of synergistic pH/H. Bioorganic chemistry, 119105510. https://doi.org/10.1016/j.bioorg.2021.105510
Liu, Jun, et al. "Construction of synergistic pH/H." Bioorganic chemistry vol. 119 (2021): 105510. doi: https://doi.org/10.1016/j.bioorg.2021.105510
Liu J, Si S, Xu J, Xue P, Li K. Construction of synergistic pH/H. Bioorg Chem. 2021 Nov 23;119:105510. doi: 10.1016/j.bioorg.2021.105510. Epub 2021 Nov 23. PMID: 34847429.
Copy Download .nbib Format: NLM
Construction of synergistic pH/H.

Bioorganic chemistry

Liu J, Si S, Xu J, Xue P, Li K.
PMID: 34847429
Bioorg Chem. 2021 Nov 23;119:105510. doi: 10.1016/j.bioorg.2021.105510. Epub 2021 Nov 23.

We have developed a real-time and multifunctional doxifluridine-conjugate prodrug (LYX), which involved the preliminary methylfluorescein with 5-fluorouracil linker as protecting group, the targeting biotin unit, and a model therapeutic drug (doxifluridine). The shielding group (5'-DFUR) was found to be...

Cite
Liu J, Si S, Xu J, et al. Construction of synergistic pH/H. Bioorg Chem. 2021;119:105510doi: 10.1016/j.bioorg.2021.105510.
Liu, J., Si, S., Xu, J., Xue, P., & Li, K. (2021). Construction of synergistic pH/H. Bioorganic chemistry, 119105510. https://doi.org/10.1016/j.bioorg.2021.105510
Liu, Jun, et al. "Construction of synergistic pH/H." Bioorganic chemistry vol. 119 (2021): 105510. doi: https://doi.org/10.1016/j.bioorg.2021.105510
Liu J, Si S, Xu J, Xue P, Li K. Construction of synergistic pH/H. Bioorg Chem. 2021 Nov 23;119:105510. doi: 10.1016/j.bioorg.2021.105510. Epub 2021 Nov 23. PMID: 34847429.
Copy Download .nbib Format: NLM
Construction of synergistic pH/H.

Bioorganic chemistry

Liu J, Si S, Xu J, Xue P, Li K.
PMID: 34847429
Bioorg Chem. 2021 Nov 23;119:105510. doi: 10.1016/j.bioorg.2021.105510. Epub 2021 Nov 23.

We have developed a real-time and multifunctional doxifluridine-conjugate prodrug (LYX), which involved the preliminary methylfluorescein with 5-fluorouracil linker as protecting group, the targeting biotin unit, and a model therapeutic drug (doxifluridine). The shielding group (5'-DFUR) was found to be...

Cite
Liu J, Si S, Xu J, et al. Construction of synergistic pH/H. Bioorg Chem. 2021;119:105510doi: 10.1016/j.bioorg.2021.105510.
Liu, J., Si, S., Xu, J., Xue, P., & Li, K. (2021). Construction of synergistic pH/H. Bioorganic chemistry, 119105510. https://doi.org/10.1016/j.bioorg.2021.105510
Liu, Jun, et al. "Construction of synergistic pH/H." Bioorganic chemistry vol. 119 (2021): 105510. doi: https://doi.org/10.1016/j.bioorg.2021.105510
Liu J, Si S, Xu J, Xue P, Li K. Construction of synergistic pH/H. Bioorg Chem. 2021 Nov 23;119:105510. doi: 10.1016/j.bioorg.2021.105510. Epub 2021 Nov 23. PMID: 34847429.
Copy Download .nbib Format: NLM
Construction of synergistic pH/H.

Bioorganic chemistry

Liu J, Si S, Xu J, Xue P, Li K.
PMID: 34847429
Bioorg Chem. 2021 Nov 23;119:105510. doi: 10.1016/j.bioorg.2021.105510. Epub 2021 Nov 23.

We have developed a real-time and multifunctional doxifluridine-conjugate prodrug (LYX), which involved the preliminary methylfluorescein with 5-fluorouracil linker as protecting group, the targeting biotin unit, and a model therapeutic drug (doxifluridine). The shielding group (5'-DFUR) was found to be...

Cite
Liu J, Si S, Xu J, et al. Construction of synergistic pH/H. Bioorg Chem. 2021;119:105510doi: 10.1016/j.bioorg.2021.105510.
Liu, J., Si, S., Xu, J., Xue, P., & Li, K. (2021). Construction of synergistic pH/H. Bioorganic chemistry, 119105510. https://doi.org/10.1016/j.bioorg.2021.105510
Liu, Jun, et al. "Construction of synergistic pH/H." Bioorganic chemistry vol. 119 (2021): 105510. doi: https://doi.org/10.1016/j.bioorg.2021.105510
Liu J, Si S, Xu J, Xue P, Li K. Construction of synergistic pH/H. Bioorg Chem. 2021 Nov 23;119:105510. doi: 10.1016/j.bioorg.2021.105510. Epub 2021 Nov 23. PMID: 34847429.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 34 entries